PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 128 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Fedratinib December 23, 2020 Reunión anual de la American Society of Clinical Oncology de 2023:... May 25, 2023 Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... February 9, 2021 What can elephants teach us about cancer? August 12, 2023 Load more HOT NEWS Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in... Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... Brentuximab May Mean Less Radiation for Children, Teens with Hodgkin Lymphoma
